IORT market seen growing to $1.75 billion by 2030

The intraoperative radiotherapy market is projected to rise from $1.08 billion in 2025 to $1.19 billion in 2026, with long-term growth driven by rising cancer cases and demand for more precise treatment. North America leads today, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Intraoperative radiotherapy, or IORT, delivers radiation during surgery and can reduce damage to healthy tissue. - The market is expanding as cancer rates climb and hospitals look for shorter, more targeted treatment options. - The segment is projected to reach $1.75 billion by 2030, signaling sustained demand for advanced oncology tools.

What happened: - The Business Research Company released a 2026 global market report on the competitive landscape of the intraoperative radiotherapy market. - The report says the market will grow from $1.08 billion in 2025 to $1.19 billion in 2026. - The report forecasts a compound annual growth rate of 10.6% from 2025 to 2026 and 10.1% through 2030. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific will be the fastest-growing region over the forecast period.

The details: - IORT administers a concentrated dose of ionizing radiation directly to the tumor or tumor bed during surgery. - The approach is designed to target cancer cells precisely while protecting nearby healthy tissue. - IORT can reduce the need for follow-up external radiotherapy. - The market’s recent growth is tied to rising cancer rates, higher demand for targeted radiation, shorter treatment times, investment in advanced oncology facilities, and broader use of image-guided surgery. - Future growth drivers include personalized cancer treatment, lower radiation exposure to healthy tissue, wider acceptance of intraoperative technologies, more specialized oncology centers, and demand for single-session radiation therapy. - Key trends include a shift toward single-session treatment, more precise radiation delivery during surgery, compact radiation devices, integrated treatment planning and dosimetry, and minimally invasive techniques. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The report also adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables. - The company offers a free sample of the report and a full version of the market report through its website. - More information is available in the free sample report and the full market report.

Between the lines: - The market forecast points to a niche but growing part of cancer care that favors precision and speed over longer multi-session radiation regimens. - The regional split suggests mature adoption in North America and a growth runway in Asia-Pacific as access to cancer care expands. - The report’s added analytics tools indicate stronger interest from buyers, investors, and suppliers in comparing markets and vendors more quickly.

What's next: - Demand will likely track cancer incidence, especially as the World Health Organization projects new cases will rise to more than 35 million by 2050. - Oncology providers may continue shifting toward technologies that support single-session treatment and minimize healthy tissue exposure. - Competition among global companies in the IORT market is likely to intensify as specialized centers expand and equipment becomes more compact and integrated.

The bottom line: - IORT is moving from a specialized surgical option to a faster-growing oncology market shaped by rising cancer burden, precision treatment demand, and technology upgrades.